
Laserfiche Named a Leader in Nucleus Research Content Services and Collaboration Value Matrix 2025
'As a leader in this year's Value Matrix, Laserfiche was rated highest in usability for its AI productivity tools, new administration hub, process automation and integration capabilities.' — Evelyn McMullen, Research Manager, Nucleus Research Share
'As a leader in this year's Value Matrix, Laserfiche was rated highest in usability for its AI productivity tools, new administration hub, process automation and integration capabilities,' said Evelyn McMullen, research manager at Nucleus Research and author of the report.
CSC as a Strategic Advantage: AI-powered Information Management
Recently released Laserfiche AI-powered features are aimed at boosting productivity even further and enabling automation at scale. Smart Fields, an out-of-the-box intelligent capture tool, allows customers to extract data automatically using natural language instructions, no matter the source or format. Smart Chat provides an intuitive chat interface that enables users to quickly gain insights from their repository content.
'As AI matures at an accelerated pace, vendors in the CSC market have the unique advantage of managing both structured and unstructured data from across the entirety of an organization,' the report's Market Overview states.
Laserfiche AI alongside powerful workflow automation, information governance and records management tools create new opportunities for organizational efficiency. Customers across industries use Laserfiche to increase productivity, create competitive advantage and drive growth.
'Laserfiche gives us the forms and workflow processes as well as data integration that enable efficiency at scale,' said Airline Hydraulics Chief Technology Officer Todd Schnirel. 'Our Laserfiche-powered process improvements have supported us in achieving a significant increase in net revenue while adding very little operating expense.'
'Being ranked a leader for 10 consecutive years is a testament to our product innovation,' said Thomas Phelps, senior vice president of corporate strategy and CIO at Laserfiche. 'Our top ranking in usability reflects our core value of putting people first and our commitment to delivering intuitive solutions that empower users.'
To learn more about Laserfiche's position in the Content Services and Collaboration market, download the report here.
About Laserfiche
Laserfiche is a leading enterprise platform that helps organizations digitally transform operations and manage their content with AI-powered solutions. Through scalable workflows, customizable forms, no-code templates and AI-enabled capabilities, the Laserfiche® document management platform accelerates how business gets done. Trusted by organizations of all sizes — from startups to Fortune 500 enterprises — Laserfiche empowers teams to boost productivity, foster collaboration, and deliver a superior customer experience at scale. Headquartered in Long Beach, California, Laserfiche operates globally, with offices across North America, Europe, and Asia.
Connect with Laserfiche:
Laserfiche Blog | X | LinkedIn | Facebook | YouTube
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
10 hours ago
- Business Wire
Terra Firma Energy Welcome UK Government Consultation on Hydrogen Blending into Great Britains Gas Transmission Network
LONDON--(BUSINESS WIRE)--At Terra Firma Energy, we welcome the UK Government's consultation into the blending of Hydrogen into Britain's Gas Transmission Network as a timely and positive step forward for both the UK's decarbonisation goals and the future of flexible power generation. All our projects are engineered to be hydrogen-ready from the outset, ensuring long-term operational flexibility and resilience in a rapidly evolving energy landscape. By anticipating changes in fuel supply and regulatory frameworks, we have future-proofed our generation assets to adapt quickly to low-carbon solutions like hydrogen blending. The ability to support hydrogen integration, even at early-stage blend levels, reinforces our commitment to sustainable innovation and positions our portfolio to contribute meaningfully to a net zero grid. Terra Firma Energy welcome UK Government Consultation on Hydrogen Blending into Great Britains Gas Transmission Network. Share The Department for Energy Security and Net Zero (DESNZ) has launched a new consultation exploring the potential for blending low-carbon hydrogen into Great Britain's gas transmission network. Following previous consultations on hydrogen blending into local distribution networks, the government is now seeking views on whether introducing hydrogen at the transmission level - the high-pressure National Transmission System (NTS) - could offer strategic and economic value. A Step Toward Net Zero Hydrogen is seen as a key player in the UK's push to reach net zero emissions by 2050. Blending low-carbon hydrogen with natural gas could offer a transitional path, supporting early-stage hydrogen production while reducing the carbon intensity of the existing gas network. DESNZ is currently evaluating whether to enable blending of up to 2% hydrogen by volume into the NTS. This small percentage could act as an 'off-taker of last resort' for hydrogen producers, providing a backup market when dedicated customers are not available. Balancing Innovation with Risk The consultation outlines both the potential benefits and challenges. While hydrogen blending could support the growth of the hydrogen economy and help manage electricity system constraints, it also raises concerns for industrial users connected to the transmission system. Many of these users rely on stable, high-quality gas supplies, and even a 2% hydrogen blend could affect equipment performance, increase costs, or require infrastructure upgrades. Terra Firma Energy have been proactive in ensuring all our projects have been built utilising hydrogen ready generation sets that can accommodate a 20% blend of hydrogen into the network. Studies cited in the consultation show that most transmission-connected users could technically handle a 2% blend with minimal changes, though feasibility studies and equipment modifications may still be necessary. At higher blends (5% or 20%), the risks and costs escalate significantly. Cross-Border Considerations The UK's ability to blend hydrogen is also influenced by developments in the EU. Under the EU Hydrogen and Decarbonised Gas Market Package, Member States can blend up to 2% hydrogen by volume, but are not required to do so. This creates potential interoperability issues with the UK's gas inter-connectors to Ireland, Belgium, and the Netherlands - especially if hydrogen blends exceed that threshold.


Business Upturn
a day ago
- Business Upturn
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE:HIMS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025, both dates inclusive (the 'Class Period'). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Additionally, the Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material facts, including that: (1) the communication between Hims and the pharmaceutical company Novo Nordisk A/S ('Novo') would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers; (2) Novo approved of Hims' offerings of compounded semaglutide products under the 'personalization' exception; (3) branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and (4) Defendants made positive statements abou the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products. If you purchased or otherwise acquired Hims & Hers shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Yahoo
a day ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio